News › Industry News, Patient Care

FDA Issues Alert for Counterfeit Botox Across Multiple U.S. States

April 17, 2024
Vial and needle

The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie’s Botox were given to consumers for cosmetic purposes in multiple states.

The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox.

As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.

Read more at Reuters >>

View the alert at U.S. Food & Drug Administration >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today’s Modern Aesthetics Practices
    • Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin
    • Merz Aesthetics’ Ultherapy PRIME Gains FDA Clearance for Knee Skin Laxity
    • USA Payments Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Accepts Supplemental Biologics License Application for Botox Cosmetic for Masseter Muscle Prominence
Advertisement